Miodia (Cyclobenzaprine)

Cyclobenzaprine acts centrally by inhibiting the presynaptic reuptake of norepinephrine, increasing its concentration in the spinal cord. This dampens reflexes that maintain muscle tone, thereby decreasing tonic somatic motor activity and producing muscle relaxation without directly acting on the muscle fibers.

The appropriate dose of cyclobenzaprine is determined by the prescribing healthcare professional based on the individual’s condition, response, and overall health status. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for cyclobenzaprine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To request Miodia, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Cyclobenzaprine is a centrally acting muscle relaxant with a relatively long half‑life, offering once‑ or twice‑daily dosing in many cases. Compared with short‑acting agents like methocarbamol, it may provide more sustained relief but can also have a higher incidence of drowsiness, requiring careful patient selection.

Miodia should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and heat sources to maintain stability and potency throughout its shelf life.

Miodia is taken orally, usually with a full glass of water. The tablet should be swallowed whole and not chewed or crushed, unless the prescriber provides specific instructions for an alternative administration method.

Serious adverse events include cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and rare neuropsychiatric effects like hallucinations or psychosis. Patients should seek immediate medical attention if they experience chest pain, difficulty breathing, rash, or unusual mental changes.

Cyclobenzaprine is contraindicated in individuals with known hypersensitivity to the drug, those who have taken monoamine oxidase inhibitors within the past 14 days, and patients with uncontrolled narrow‑angle glaucoma. Caution is also advised for the elderly and for patients with significant hepatic or renal impairment.